Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

← catalyst calendar

NCT05312879 · readout in 653 d

Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

466estimated

Sites

318

Countries

Belgium, Brazil, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-03-30

actual

When the study began enrolling

Primary completion

2028-06-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-05-07

estimated

The whole study's end, after follow-up

First posted

2022-04-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Proteinuric Kidney Disease

Interventions

Drug: VX-147
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)

measured From Baseline to Week 48

Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim Analysis

measured From Baseline Through >= Week 48

Part A: eGFR Slope Assessed at Final Analysis

measured From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)

Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

measured Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)

Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed